Acetylcarnitine – (3040-38-8)

Acetyl-L-carnitine (ALCAR) is a naturally occurring compound in the human body and is also available as a dietary supplement. It plays a crucial role in energy production by facilitating the transport of fatty acids into the mitochondria for oxidation. ALCAR is formed by the reaction of acetyl-CoA with carnitine, a process vital for the Krebs cycle and ATP production.

Research indicates that ALCAR may offer several health benefits. It has been studied for its potential to reduce pain from peripheral neuropathy, with some evidence suggesting it improves electromyographic parameters. However, a 2019 Cochrane review found insufficient evidence to confirm its effectiveness in reducing pain after 6 to 12 months of treatment. ALCAR has also been investigated for its role in chemotherapy-induced peripheral neuropathy, with mixed results. Some studies suggest it may alleviate symptoms in patients treated with paclitaxel and cisplatin, while others indicate it could worsen conditions in taxane therapy.

In the context of male infertility, studies have shown mixed outcomes, with some reporting improved sperm motility and others finding no significant relationship. ALCAR has been explored for its potential in treating dementia, particularly Alzheimer’s disease, but a 2003 Cochrane review found a lack of efficacy and poor understanding of its pharmacology. For depression, a 2018 meta-analysis concluded that ALCAR supplementation significantly decreases depressive symptoms compared to placebo, with fewer adverse effects than established antidepressants, though it was not more effective than placebo in younger subjects.

ALCAR has also been studied in the management of hepatic encephalopathy, where it improves blood ammonia levels and offers modest psychometric score improvements. Additionally, it has been investigated for its role in treating fragile X syndrome, but current evidence does not support its use for improving intellectual functioning or hyperactive behavior in children with this condition.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Acetyl-L-carnitine (ALCAR) is a naturally occurring compound in the human body and is also available as a dietary supplement. It plays a crucial role in energy production by facilitating the transport of fatty acids into the mitochondria for oxidation. ALCAR is formed by the reaction of acetyl-CoA with carnitine, a process vital for the Krebs cycle and ATP production.

Research indicates that ALCAR may offer several health benefits. It has been studied for its potential to reduce pain from peripheral neuropathy, with some evidence suggesting it improves electromyographic parameters. However, a 2019 Cochrane review found insufficient evidence to confirm its effectiveness in reducing pain after 6 to 12 months of treatment. ALCAR has also been investigated for its role in chemotherapy-induced peripheral neuropathy, with mixed results. Some studies suggest it may alleviate symptoms in patients treated with paclitaxel and cisplatin, while others indicate it could worsen conditions in taxane therapy.

In the context of male infertility, studies have shown mixed outcomes, with some reporting improved sperm motility and others finding no significant relationship. ALCAR has been explored for its potential in treating dementia, particularly Alzheimer’s disease, but a 2003 Cochrane review found a lack of efficacy and poor understanding of its pharmacology. For depression, a 2018 meta-analysis concluded that ALCAR supplementation significantly decreases depressive symptoms compared to placebo, with fewer adverse effects than established antidepressants, though it was not more effective than placebo in younger subjects.

ALCAR has also been studied in the management of hepatic encephalopathy, where it improves blood ammonia levels and offers modest psychometric score improvements. Additionally, it has been investigated for its role in treating fragile X syndrome, but current evidence does not support its use for improving intellectual functioning or hyperactive behavior in children with this condition.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Acetylcarnitine
https://pubchem.ncbi.nlm.nih.gov/compound/7045767
https://www.medchemexpress.com/L-Acetylcarnitine.html
https://www.medkoo.com/products/17285
https://www.sciencedirect.com/topics/neuroscience/acetylcarnitine
https://pubmed.ncbi.nlm.nih.gov/10608918/
Other Names

Acetyl-L-carnitine, O-Acetyl-L-carnitine, L-ACETYLCARNITINE

IUPAC Name

(3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate

CAS

3040-38-8

Molecular Weight

203.24

Molecular Formula

C9H17NO4

SMILES

CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C

No products in the cart.